| Evolution of low HER2 expression between early and advanced-stage breast cancer P Tarantino, S Gandini, E Nicolò, P Trillo, F Giugliano, P Zagami, ... European Journal of Cancer 163, 35-43, 2022 | 120 | 2022 |
| Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives E Nicolò, F Giugliano, L Ascione, P Tarantino, C Corti, SM Tolaney, ... Cancer Treatment Reviews 106, 102395, 2022 | 77 | 2022 |
| Antibody–drug conjugates for the treatment of breast cancer C Corti, F Giugliano, E Nicolò, L Ascione, G Curigliano Cancers 13 (12), 2898, 2021 | 56 | 2021 |
| Bystander effect of antibody–drug conjugates: fact or fiction? F Giugliano, C Corti, P Tarantino, F Michelini, G Curigliano Current oncology reports 24 (7), 809-817, 2022 | 54 | 2022 |
| First line treatment of BRAF mutated advanced melanoma: Does one size fit all? F Giugliano, E Crimini, P Tarantino, P Zagami, J Uliano, C Corti, ... Cancer Treatment Reviews 99, 102253, 2021 | 33 | 2021 |
| Margetuximab for the treatment of HER2-positive metastatic breast cancer P Tarantino, S Morganti, J Uliano, F Giugliano, E Crimini, G Curigliano Expert Opinion on Biological Therapy 21 (2), 127-133, 2021 | 32 | 2021 |
| Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies G Antonarelli, F Giugliano, C Corti, M Repetto, P Tarantino, G Curigliano Pharmaceuticals 14 (9), 884, 2021 | 23 | 2021 |
| Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions M Repetto, E Crimini, F Giugliano, S Morganti, C Belli, G Curigliano Expert Review of Clinical Pharmacology 14 (10), 1233-1252, 2021 | 22 | 2021 |
| Pregnancy after breast cancer in young BRCA carriers: an international hospital-based cohort study M Lambertini, E Blondeaux, E Agostinetto, AS Hamy, HJ Kim, A Di Meglio, ... JAMA 331 (1), 49-59, 2024 | 21 | 2024 |
| Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review D Trapani, F Giugliano, J Uliano, VAA Zia, A Marra, G Viale, E Ferraro, ... Breast Cancer Research and Treatment 187 (2), 323-337, 2021 | 20 | 2021 |
| HER2-low breast cancer: a new subtype? C Corti, F Giugliano, E Nicolo, P Tarantino, C Criscitiello, G Curigliano Current Treatment Options in Oncology 24 (5), 468-478, 2023 | 19 | 2023 |
| Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and … L Pala, F Conforti, M Saponara, T De Pas, F Giugliano, EO Salè, C Jemos, ... Seminars in Oncology 47 (5), 302-304, 2020 | 14 | 2020 |
| Harmonizing PD-L1 testing in metastatic triple negative breast cancer F Giugliano, G Antonarelli, P Tarantino, J Cortes, HS Rugo, G Curigliano Expert opinion on biological therapy 22 (3), 345-348, 2022 | 11 | 2022 |
| Emerging treatment landscape of non-muscle invasive bladder cancer C Valenza, G Antonarelli, F Giugliano, G Aurilio, E Verri, A Briganti, ... Expert Opinion on Biological Therapy 22 (6), 717-734, 2022 | 10 | 2022 |
| Unlocking the resistance to anti-HER2 treatments in breast cancer: the issue of HER2 spatial distribution F Giugliano, A Carnevale Schianca, C Corti, M Ivanova, N Bianco, ... Cancers 15 (5), 1385, 2023 | 7 | 2023 |
| Breast cancer with brain metastasis: molecular insights and clinical management M Ivanova, FM Porta, F Giugliano, C Frascarelli, E Sajjadi, K Venetis, ... Genes 14 (6), 1160, 2023 | 6 | 2023 |
| Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases P Trillo, J Sandoval, D Trapani, E Nicolò, P Zagami, F Giugliano, ... European Journal of Cancer 185, 119-130, 2023 | 6 | 2023 |
| HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era F Giugliano, G Curigliano, P Tarantino European Journal of Cancer Prevention 32 (2), 149-154, 2023 | 5 | 2023 |
| SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis F Giugliano, PA Zucali, G Galli, Z Ballatore, C Corti, PT Aliaga, J Uliano, ... European Journal of Cancer 166, 202-207, 2022 | 4 | 2022 |
| PARP inhibitors for breast cancer treatment: a review S Morganti, A Marra, C De Angelis, A Toss, L Licata, F Giugliano, ... JAMA oncology, 2024 | 3 | 2024 |
Paolo TarantinoDana-Farber Cancer Institute, Harvard Medical School在 dfci.harvard.edu 的电子邮件经过验证
